Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase

BACKGROUND: Despite overexpression of the ErbB (EGFR/HER2/ErbB3/ErbB4) family in castration-resistant prostate cancer (CRPC), some inhibitors of this family, including the dual EGFR/HER2 inhibitor lapatinib, failed in Phase II clinical trials. Hence, we investigated mechanisms of lapatinib resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Jathal, Maitreyee K., Steele, Thomas M., Siddiqui, Salma, Mooso, Benjamin A., D’Abronzo, Leandro S., Drake, Christiana M., Whang, Young E., Ghosh, Paramita M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738116/
https://www.ncbi.nlm.nih.gov/pubmed/31209328
http://dx.doi.org/10.1038/s41416-019-0496-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738116/
https://www.ncbi.nlm.nih.gov/pubmed/31209328
http://dx.doi.org/10.1038/s41416-019-0496-4

Ejemplares similares